PURPOSE: Osteonecrosis of the jaw (ONJ) is a devastating side effect of long-term bisphosphonate (BP) use. We present the largest case series from a single department. MATERIALS AND METHODS: This case series included 101 ONJ patients. Data on demographics, medical background, type and duration of BP use, possible triggering events, mode of therapy, and outcome were recorded. RESULTS: ONJ was associated with intravenous BPs in 85 patients and with oral BPs in 16 patients. It was diagnosed after 48, 27, and 67 months of pamidronate, zoledronic acid, and alendronate use, respectively. Long-term antibiotics and minimal surgical procedures resulted in complete or partial healing in 18% and 52% of the patients, respectively; 30% had no response. There was no association between ONJ and diabetes, steroid and antiangiogenic treatment, or underlying periodontal disease. Diagnostic biopsies aggravated lesions without being informative about pathogenesis. A conservative regimen is our treatment of choice. CONCLUSION: Solutions for decreasing morbidity and poor outcome of ONJ remain elusive.
PURPOSE:Osteonecrosis of the jaw (ONJ) is a devastating side effect of long-term bisphosphonate (BP) use. We present the largest case series from a single department. MATERIALS AND METHODS: This case series included 101 ONJ patients. Data on demographics, medical background, type and duration of BP use, possible triggering events, mode of therapy, and outcome were recorded. RESULTS: ONJ was associated with intravenous BPs in 85 patients and with oral BPs in 16 patients. It was diagnosed after 48, 27, and 67 months of pamidronate, zoledronic acid, and alendronate use, respectively. Long-term antibiotics and minimal surgical procedures resulted in complete or partial healing in 18% and 52% of the patients, respectively; 30% had no response. There was no association between ONJ and diabetes, steroid and antiangiogenic treatment, or underlying periodontal disease. Diagnostic biopsies aggravated lesions without being informative about pathogenesis. A conservative regimen is our treatment of choice. CONCLUSION: Solutions for decreasing morbidity and poor outcome of ONJ remain elusive.
Authors: Philipp Stockmann; Moritz Burger; Cornelius von Wilmowsky; Tobias Ebker; Rainer Lutz; Anne Bauersachs; Emeka Nkenke; Friedrich Wilhelm Neukam; Falk Wehrhan Journal: Clin Oral Investig Date: 2013-08-29 Impact factor: 3.573
Authors: L Lo Russo; D Ciavarella; C Buccelli; O Di Fede; G Campisi; L Lo Muzio; G Pellegrino; P Di Lorenzo Journal: Br Dent J Date: 2014-09 Impact factor: 1.626
Authors: S Lekamwasam; J D Adachi; D Agnusdei; J Bilezikian; S Boonen; F Borgström; C Cooper; A Diez Perez; R Eastell; L C Hofbauer; J A Kanis; B L Langdahl; O Lesnyak; R Lorenc; E McCloskey; O D Messina; N Napoli; B Obermayer-Pietsch; S H Ralston; P N Sambrook; S Silverman; M Sosa; J Stepan; G Suppan; D A Wahl; J E Compston Journal: Osteoporos Int Date: 2012-03-21 Impact factor: 4.507
Authors: Paula Baptistella de Lima; Veruska Lima Moura Brasil; Jurema Freire Lisboa de Castro; Flávia Maria de Moraes Ramos-Perez; Fábio Abreu Alves; Maria Luiza dos Anjos Pontual; Danyel Elias da Cruz Perez Journal: Support Care Cancer Date: 2015-03-11 Impact factor: 3.603
Authors: Bevin C English; Caitlin E Baum; David E Adelberg; Tristan M Sissung; Paul G Kluetz; William L Dahut; Douglas K Price; William D Figg Journal: Ther Clin Risk Manag Date: 2010-11-19 Impact factor: 2.423